CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Revolutionary technology will further boost OneSource’s scientific services offerings
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
GSK and Flagship to jointly fund up to $150 million upfront
Campaign launched to spread awareness regarding dengue prevention and control
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
